Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Mandel

Showing results (81-90 of 221) with videos related to

Pageof 23
Sort By:
European Urology Focus|December 6, 2024
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE DataBenedikt Hoeh, Mike Wenzel, Zhe Tian, et al.
The Prostate|July 19, 2023
Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapyMike Wenzel, Cristina C Garcia, Benedikt Hoeh, et al.
Clinical Genitourinary Cancer|December 17, 2013
EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancerMatthias May, Maximilian Burger, Sabine Brookman-May, et al.
World Journal of Urology|March 24, 2026
Influence of concomitant distant lymph node metastases in metastatic hormone-sensitive prostate cancer patients with bone metastasesMike Wenzel, Benedikt Lauer, Vincenzo Giuseppe Mühlthaler, et al.
European Urology Open Science|July 22, 2024
Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer PatientsMike Wenzel, Carolin Siech, Benedikt Hoeh, et al.
Diagnostics (Basel, Switzerland)|June 19, 2024
Transition from Transrectal to Transperineal MRI-Fusion Prostate Biopsy Does Not Comprise Detection Rates of Clinically Significant Prostate Cancer at a Tertiary Care CenterBenedikt Hoeh, Mike Wenzel, Clara Humke, et al.
World Journal of Urology|November 2, 2024
Influence of metastatic sites and burden on oncological outcomes in patients progressing to metastatic castration resistant prostate cancerMike Wenzel, Benedikt Hoeh, Clara Humke, et al.
Theranostics|March 14, 2025
Cancer-control outcomes with [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patientsMike Wenzel, Carolin Siech, Cristina Cano Garcia, et al.
Urologic Oncology|July 28, 2024
Organ-confined pT2 ISUP4/5 vs. nonorgan confined pT3/4 ISUP2 vs. ISUP3 prostate cancer: Differences in biochemical recurrence-free survival after radical prostatectomyCarolin Siech, Benedikt Hoeh, Eike Rohlfsen, et al.
The Prostate|May 30, 2024
Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patientsMike Wenzel, Benedikt Hoeh, Fabienne Hurst, et al.
Pageof 23

Showing results (81-90 of 221) with videos related to

Sort By:
Pageof 23
European Urology Focus|December 6, 2024
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE DataBenedikt Hoeh, Mike Wenzel, Zhe Tian, et al.
The Prostate|July 19, 2023
Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapyMike Wenzel, Cristina C Garcia, Benedikt Hoeh, et al.
Clinical Genitourinary Cancer|December 17, 2013
EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancerMatthias May, Maximilian Burger, Sabine Brookman-May, et al.
World Journal of Urology|March 24, 2026
Influence of concomitant distant lymph node metastases in metastatic hormone-sensitive prostate cancer patients with bone metastasesMike Wenzel, Benedikt Lauer, Vincenzo Giuseppe Mühlthaler, et al.
European Urology Open Science|July 22, 2024
Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer PatientsMike Wenzel, Carolin Siech, Benedikt Hoeh, et al.
Diagnostics (Basel, Switzerland)|June 19, 2024
Transition from Transrectal to Transperineal MRI-Fusion Prostate Biopsy Does Not Comprise Detection Rates of Clinically Significant Prostate Cancer at a Tertiary Care CenterBenedikt Hoeh, Mike Wenzel, Clara Humke, et al.
World Journal of Urology|November 2, 2024
Influence of metastatic sites and burden on oncological outcomes in patients progressing to metastatic castration resistant prostate cancerMike Wenzel, Benedikt Hoeh, Clara Humke, et al.
Theranostics|March 14, 2025
Cancer-control outcomes with [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patientsMike Wenzel, Carolin Siech, Cristina Cano Garcia, et al.
Urologic Oncology|July 28, 2024
Organ-confined pT2 ISUP4/5 vs. nonorgan confined pT3/4 ISUP2 vs. ISUP3 prostate cancer: Differences in biochemical recurrence-free survival after radical prostatectomyCarolin Siech, Benedikt Hoeh, Eike Rohlfsen, et al.
The Prostate|May 30, 2024
Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patientsMike Wenzel, Benedikt Hoeh, Fabienne Hurst, et al.
Pageof 23